Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis
This study has been completed.
Sponsored by: Alcon Research
Information provided by: Alcon Research
ClinicalTrials.gov Identifier: NCT00772304
  Purpose

To compare patient perceptions of the sensory attributes, including taste and aftertaste, of Olopatadine relative to azelastine when administered as a single dose in patients with allergic rhinitis.


Condition Intervention Phase
Allergic Rhinitis
Drug: Olopatadine 0.6%
Drug: Azelastine 137mcg
Phase IV

MedlinePlus related topics: Taste and Smell Disorders
Drug Information available for: Olopatadine Azelastine Azelastine hydrochloride
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Crossover Assignment

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Taste of the medication [ Time Frame: 5 min ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Taste and aftertaste of medication [ Time Frame: 5 min, 45 min. ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: October 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Olopatadine 0.6%
Drug: Olopatadine 0.6%
single dose; 2 sprays per nostril
2: Active Comparator
Azelastine 137mcg
Drug: Azelastine 137mcg
single dose; 2 sprays per nostril

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Must have a history (at least 2 yrs) of allergic rhinitis and be symptomatic at time of enrollment
  2. 18 yrs of age or older
  3. Read and sign informed consent
  4. Females of childbearing potential may participate if: are non-breast feeding, have negative urine pregnancy test at visit 1, agree to take urine pregnancy test upon exiting study, do not intend to become pregnant during the study, are using adequate methods of birth control.

Exclusion Criteria:

  1. History of intolerance or hypersensitivity to any component of the study medications, including benzalkonium chloride.
  2. Any disease or systemic disorder that may complicate or interfere with investigation or evaluation of the study medications (including but not limited to): Rhinitis medicamentosa, large obstructive nasal polyps, history (w/in last 3 months) of nasal septic ulcers, nasal surgery or nasal trauma, history or evidence of nasolacrimal drainage system malfunction, history (w/in 30 days) or evidence of sinusitis or upper or lower respiratory infection.
  3. Impairment of sense of tast or smell (self reported)
  4. Asthma, except for mild, intermittent asthma (nat'l Asthma guidelines)
  5. Congestion, that in the opinion of the investigator, that would interfere with successful nasal drug administration/absorption
  6. Patients w/a severe impairment of nasal breathing
  7. Anatomic abnormalities of as identified by nasal examination
  8. History of or current severe or uncontrolled cardiovascular, hepatic, renal and/or other disease/illness that could interfere w/study.
  9. History of (w/in past 12 months) or ongoing clinically relevant electrolyte abnormalities.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00772304

Locations
United States, Texas
Alcon Call Center for Trial Locations
Fort Worth, Texas, United States, 76134
Sponsors and Collaborators
Alcon Research
  More Information

Responsible Party: Alcon Research ( Michael Edwards, PhD\Global Scientific Market Affairs )
Study ID Numbers: SMA-08-21
Study First Received: October 13, 2008
Last Updated: November 10, 2008
ClinicalTrials.gov Identifier: NCT00772304  
Health Authority: United States: Institutional Review Board

Keywords provided by Alcon Research:
rhinitis

Study placed in the following topic categories:
Otorhinolaryngologic Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Histamine phosphate
Rhinitis
Azelastine
Olopatadine
Histamine

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Respiratory System Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Histamine Agents
Anti-Asthmatic Agents
Enzyme Inhibitors
Anti-Allergic Agents
Lipoxygenase Inhibitors
Pharmacologic Actions
Nose Diseases
Histamine Antagonists
Autonomic Agents
Analgesics, Non-Narcotic
Histamine H1 Antagonists
Peripheral Nervous System Agents
Histamine H1 Antagonists, Non-Sedating
Antirheumatic Agents
Bronchodilator Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 14, 2009